Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(22):1632-1633; doi:10.1093/jnci/dji413
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sabichi, A. L.
Right arrow Articles by Lippman, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabichi, A. L.
Right arrow Articles by Lippman, S. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

RAR{beta}1': Primed To Fight Retinoid Resistance in Lung Carcinogenesis

Anita L. Sabichi, Xiaochun Xu, Scott M. Lippman

Affiliations of authors: Departments of Clinical Cancer Prevention (ALS, XX, SML) and Thoracic/Head and Neck Medical Oncology (ALS, SML), The University of Texas M. D. Anderson Cancer Center, Houston

Correspondence to: Anita L. Sabichi, MD, Department of Clinical Cancer Prevention—Unit 1360, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., P.O. Box 301439, Houston, TX 77230-1439 (e-mail: asabichi@mdanderson.org).

The first 10% of the full text of this article appears below.

Retinoids (vitamin A and its natural and synthetic analogues) have a strong preclinical record of anticarcinogenic activity in a broad range of tissue types (1). The promise of this record, however, has not been realized in clinical trials of retinoids in preventing lung cancers. The inability of retinoids to prevent second primary lung cancers in the phase III European Study on Chemoprevention with Vitamin A and N-Acetylcysteine (EUROSCAN) (2) and the Lung Intergroup Trial (LIT) (3) has substantially dampened the enthusiasm for further exploring retinoids for lung cancer treatment and prevention. The provocative article by Petty et al. (4) on a new retinoid receptor and retinoid resistance in lung . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?